Phyllis Whiteley and Dan Riskin have joined Mohr Davidow Ventures as an executive-in-residence and entrepreneur-in-residence, respectively. Both will focus on the life sciences sector. Whiteley previously was an entrepreneur-in-residence with 5AM Ventures, where she co-founded Anaphore Inc. Riskin previously was president of Interventional Dynamics Inc.
November 20, 2008, Menlo Park, CA — MDV-Mohr Davidow Ventures, a leading Silicon Valley venture capital firm, today announced the addition of Phyllis Whiteley and Dan Riskin to the firm as Executive-in-Residence and Entrepreneur-in-Residence, respectively. Each will pursue and develop start-up opportunities that provide healthcare providers and consumers more effective ways to manage health and wellness – from prevention to diagnosis to the treatment of disease.
“Phyllis and Dan bring important domain expertise and experience to the MDV team,” said MDV General Partner Sue Siegel. “They will strengthen MDV’s current investing activities in personalized medicine and expand our reach into new areas including health information systems, Health 2.0 businesses, and into the emerging area of consumer-driven medicine.”
Phyllis Whiteley brings more than 20 years experience across academics, biotech, and pharma in research, development, business, and portfolio management. Most recently she worked with 5AM Ventures where she co-founded Anaphore, Inc. Prior to her work in venture capital, Whiteley was an Officer and Senior Vice President at Perlegen Sciences, Inc. Before Perlegen, she served as Vice President, Strategic Portfolio Management for F. Hoffman La Roche. During her ten years with Roche, she held various senior management positions. Prior to her Roche tenure, Whiteley was a senior research immunologist at Merck. She holds a Ph.D. in Pharmacology from Washington University, St. Louis, Missouri. Whiteley serves on several private company boards and is on the board of the Personalized Medicine Coalition.
Dan Riskin will focus on healthcare information systems and business models as an EIR (Entrepreneur-In-Residence). He brings a diverse background with 15 years of medical expertise and 20 years of IT experience. Prior to MDV, Riskin was the President of Interventional Dynamics Inc, a medical technology R&D firm. Prior to Interventional Dynamics, Riskin was in business development at Roche Diagnostics where he worked with MIT Media Lab and BodyMedia to create and commercialize an IT-based obesity management system. In 2005, Riskin was named one of the top 35 innovators under 35 by MIT’s Technology Review.
Riskin is an acute care surgeon and intensivist. He earned a MBA with a focus in bioinformatics from MIT Sloan School of Management and completed the prestigious Biodesign Medical Technology Fellowship at Stanford in 2005. His medical training includes a MD from Boston University, surgical residency at UCLA, and a critical care fellowship at Stanford.
About MDV-Mohr Davidow Ventures
MDV-Mohr Davidow Ventures is a leading Silicon Valley-based venture capital firm that partners with exceptional entrepreneurs building breakthrough companies that disrupt incumbents or create new markets, principally through technology innovation. The firm invests in the areas of Cleantech, Information Technology, and Human Health. Category-leading life science companies funded by MDV include: Adamas Pharmaceuticals; Artemis Health; CardioDx; CELLective Diagnostics; Corventis; Crescendo Bioscience; Navigenics; Pacific Biosciences; ParAllele (AFFX); RainDance Technologies; Tethys Bioscience; The DNA Repair Company; and Ventus Medical. MDV has $2 billion under management. For more information, visit www.mdv.com.